73 articles for C He
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
20
Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERa and VEGFR-2 as anti-breast cancer agents.
China Pharmaceutical University
11
Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents.
Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University)
17
Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1.
Peking University
22
Development of 3,5-dinitrobenzoate-based 5-lipoxygenase inhibitors.
Peking University
11
Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety.
Shenyang Pharmaceutical University
33
Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors.
Peking University
19
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.
Incyte
4
Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching.
Peking University
31
Design and Synthesis of 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic Acid Derivatives as PP5 Inhibitors To Reverse Temozolomide Resistance in Glioblastoma Multiforme.
China Pharmaceutical University
31
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.
Incyte
31
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.
Incyte
1
Small molecules targeting molecular chaperones for tau regulation: Achievements and challenges.
China Pharmaceutical University
33
Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity.
China Pharmaceutical University
16
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.
Incyte
34
Discovery and Anti-Inflammatory Activity Evaluation of a Novel CDK8 Inhibitor through Upregulation of IL-10 for the Treatment of Inflammatory Bowel Disease
Anhui Medical University
47
Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine: Design, structure-activity relationship and anti-inflammatory activity in vivo.
Anhui Medical University
4
Discovery of a Novel Vascular Disrupting Agent Inhibiting Tubulin Polymerization and HDACs with Potent Antitumor Effects.
China Pharmaceutical University
42
Discovery of 1'-(1-phenylcyclopropane-carbonyl)-3H-spiro[isobenzofuran-1,3'-pyrrolidin]-3-one as a novel steroid mimetic scaffold for the potent and tissue-specific inhibition of 11β-HSD1 using a scaffold-hopping approach.
Incyte Research Institute
16
Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2.
Incyte
53
Discovery of a novel 2-spiroproline steroid mimetic scaffold for the potent inhibition of 11β-HSD1.
Incyte Research Institute
2
Discovery of bilirubin as novel P2X7R antagonist with anti-tumor activity.
Zhengzhou University
45
Discovery of spiro amide SHR902275: A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers.
Eternity Bioscience
20
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
Incyte
19
INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).
Incyte
17
Pentafluorosulfanyl-Substituted Benzopyran Analogues As New Cyclooxygenase-2 Inhibitors with Excellent Pharmacokinetics and Efficacy in Blocking Inflammation.
Guangzhou Institutes of Biomedicine and Health
1
Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors
Shenzhen Targetrx
314
Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
Beijing Tide Pharmaceutical
3
Triple combination of pure 5-HT6 receptor antagonists, acetylcholinesterase inhibitors and NMDA receptor antagonist
Suven Life Sciences
16
Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors
Boehringer Ingelheim International
4
Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
Arena Pharmaceuticals
20
LRRK2 inhibitors and methods of making and using the same
Dana-Farber Cancer Institute
11
Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same
Mebias Discovery
59
Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use
Merck Sharp & Dohme
179
Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
Allergan
26
Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
Boehringer Ingelheim International
10
Substituted azoles, antiviral active component, pharmaceutical composition, method for preparation and use thereof
Alla Chem
120
Tricyclic substituted thiadiazine dioxide compounds as BACE inhibitors, compositions and their use
Merck Sharp & Dohme
7
The SUMO1-E67 interacting loop peptide is an allosteric inhibitor of the dipeptidyl peptidases 8 and 9.
Georg-August-University of Goettingen
16
Tri-aryl/heteroaromatic cannabinoids and use thereof
The University of Tennessee Research Foundation
19
Novel biphenyl bis-sulfonamides as acetyl and butyrylcholinesterase inhibitors: Synthesis, biological evaluation and molecular modeling studies.
Government College University
5
Structure-guided design of a high affinity inhibitor to human CtBP.
University of Massachusetts Medical School
124
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
University of South Florida
11
Inhibition of fucosyltransferase VII by gallic acid and its derivatives.
Schering-Plough Research Institute
26
Discovery of novel arylpyrazole series as potent and selective opioid receptor-like 1 (ORL1) antagonists.
Banyu Pharmaceutical
4
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
Pfizer
24
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.
Bryn Mawr College
11
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
Bristol Myers Squibb
27
Synthesis and structure-activity relationships of beta- and alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy.
Pfizer